Q32 Bio Inc (QTTB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Q32 Bio Inc stock (QTTB) is currently trading at $7.25. Q32 Bio Inc PE ratio is 2.79. Q32 Bio Inc PS ratio (Price-to-Sales) is 1.84. Analyst consensus price target for QTTB is $14.33. WallStSmart rates QTTB as Hold.
- QTTB PE ratio analysis and historical PE chart
- QTTB PS ratio (Price-to-Sales) history and trend
- QTTB intrinsic value — DCF, Graham Number, EPV models
- QTTB stock price prediction 2025 2026 2027 2028 2029 2030
- QTTB fair value vs current price
- QTTB insider transactions and insider buying
- Is QTTB undervalued or overvalued?
- Q32 Bio Inc financial analysis — revenue, earnings, cash flow
- QTTB Piotroski F-Score and Altman Z-Score
- QTTB analyst price target and Smart Rating
Q32 Bio Inc
📊 No data available
Try selecting a different time range
QTTB Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Q32 Bio Inc (QTTB)
QTTB trades at a significant discount to its Graham intrinsic value of $16.46, offering a 77% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Q32 Bio Inc (QTTB) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, price/sales. Concerns around market cap. Fundamentals are solid but monitor weak areas for improvement.
Q32 Bio Inc (QTTB) Key Strengths (5)
Every $100 of shareholder equity generates $125 in profit
Keeps $85 of every $100 in revenue after operating costs
Keeps $56 of every $100 in revenue as net profit
Paying $1.84 for every $1 of annual revenue
65.60% held by institutions, strong professional interest
Supporting Valuation Data
Q32 Bio Inc (QTTB) Areas to Watch (2)
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Q32 Bio Inc (QTTB) Detailed Analysis Report
Overall Assessment
This company scores 56/100 in our Smart Analysis, earning a C grade. Out of 7 metrics analyzed, 5 register as strengths (avg 9.2/10) while 2 fall into concern territory (avg 4.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Profit Margin. Valuation metrics including Price/Sales (1.84) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 125.10%, Operating Margin at 85.40%, Profit Margin at 55.50%.
The Bear Case
The primary concerns are Market Cap, Price/Book. Some valuation metrics including Price/Book (2.33) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 125.10% currently healthy but needing to be sustained. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Operating Margin) and negatives (Market Cap, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
QTTB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
QTTB's Price-to-Sales ratio of 1.84x trades at a deep discount to its historical average of 30.2x (24th percentile). The current valuation is 98% below its historical high of 118.17x set in Feb 2020, and 300% above its historical low of 0.46x in Dec 2022. Over the past 12 months, the PS ratio has compressed from ~3.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Q32 Bio Inc (QTTB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Q32 Bio Inc operates as a stable business with moderate growth and solid fundamentals. Profit margins are strong at 55.5%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 125.1% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 55.5% and operating margin of 85.4% demonstrate strong pricing power and operational efficiency.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Q32 Bio Inc.
Bottom Line
Q32 Bio Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Q32 Bio Inc(QTTB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Q32 Bio Inc. is a pioneering biotechnology firm focused on developing innovative antibody-based therapies to address autoimmune diseases and enhance immune responses. Utilizing its proprietary technology platform, the company is advancing a robust pipeline of treatments designed to restore immune system balance. Backed by a seasoned management team and strategic collaborations, Q32 Bio is well-positioned to leverage its scientific expertise to meet significant unmet medical needs, thereby driving transformative advancements in healthcare and creating value for shareholders through sustained research and development initiatives.